LYNETTE MOON: Open Payments
NPI 1598131278 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,937 in 91 payments from 17 companies in 2025. Trend: 2023 $1,268 · 2024 $1,412 · 2025 $1,937
Food & beverage: $1,937
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 8 | $393 |
| ABBVIE INC. | 18 | $329 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $252 |
| Madrigal Pharmaceuticals | 15 | $180 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $136 |
| GENZYME CORPORATION | 3 | $112 |
| QOL Medical, LLC | 5 | $96 |
| Celltrion USA Inc. | 4 | $75 |
| Aimmune Therapeutics, Inc. | 3 | $74 |
| Lilly USA, LLC | 4 | $66 |
Products named: TREMFYA, REZDIFFRA, RINVOQ, ENTYVIO, XIFAXAN, DUPIXENT, Sucraid, EOHILIA.
Industry payments across IN — which companies pay providers there.
